Madrigal Pharmaceuticals (MDGL) has shared an update.
Madrigal Pharmaceuticals, Inc. stockholders recently backed significant changes to the company’s 2015 Amended Stock Plan, including a 750,000 share expansion and a 10-year extension through 2035. Additionally, a new one-year minimum vesting period was introduced for post-2024 awards, aligning with the firm’s clawback policies for incentive recovery. These updates were part of several key decisions made at the 2024 Annual Meeting, where stockholders also re-elected board members and ratified the appointment of PricewaterhouseCoopers LLP as their independent auditor for the upcoming fiscal year.
For a thorough assessment of MDGL stock, go to TipRanks’ Stock Analysis page.
